MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Treatments

Home
Treatments
AHSCT

BEAT-MS Trial to Compare AHSCT to MS Treatments

MStranslate
January 14, 2020
Research, Stem Cells, Treatments
Over recent years, we have seen a large expansion in the number of available treatments for people living with relapsing-remitting multiple sclerosis (RRMS).  As well as this, we have recently seen a number...
siponimod

Research Reflections: Siponimod Trial Results

MStranslate
November 21, 2019
Clinical Trials, Research, Treatments
1 Comment
In April 2018, we published the below video to our Facebook page, exploring and discussing the results of the Phase III trial of Mayzent (siponimod). With this therapy recently approved for the treatment of...
gut bacteria

Treatment With Gut Bacteria Shows Benefits In New Study

MStranslate
May 2, 2019
Research, Treatments
1 Comment
Research Summary: Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE® in an Animal Model of Multiple Sclerosis Many people living with multiple sclerosis say they have experienced...
Mavenclad

FDA Approves Second Drug For Active SPMS

MStranslate
April 1, 2019
Research, Treatments
Late last week, it was announced that Mavenclad (cladribine) received US FDA approval for the treatment of adults living with relapsing multiple sclerosis (MS). Importantly, this also includes people living...
siponimod

New Treatment Approved for Active SPMS

MStranslate
March 27, 2019
Research, Treatments
1 Comment
It was announced earlier today that Mayzent (siponimod) has received US FDA approval for the treatment of adults living with relapsing multiple sclerosis (MS).  Importantly, this also includes people living...
Cocoa

Does a Cocoa a Day Keep MS Fatigue Away?

MStranslate
March 19, 2019
Fatigue, Research, Symptoms, Treatments
1 Comment
Research Summary: A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis Fatigue is one of the most...
HSCT

HSCT Trial Shows Positive Results for RRMS

MStranslate
February 19, 2019
Research, Stem Cells, Treatments
2 Comments
Research Summary: Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A...
CORe Unit

MS Treatments Delay Progressive Disease

MStranslate
February 12, 2019
Progressive MS, Research, Treatments
Research Summary: Association of Initial Disease-Modifying With Later Conversion to Secondary Progressive Multiple Sclerosis In mid-January, we had the good fortune of getting to break some major multiple...
treatment decision

What influences the choice of treatment in MS?

MStranslate
November 28, 2018
Research, Treatments, Uncategorized
Research Summary: Understanding treatment decisions from the perspective of people with relapsing remitting multiple sclerosis: A critical interpretive synthesis The past decade has seen a number of new...
T Cell Therapy

EBV-Specific T Cell Therapy for Progressive MS

MStranslate
November 20, 2018
Epstein-Barr virus, Infection, Progressive MS, Research, Treatments
Research Summary: Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis Last week, during our Facebook Live Q&A, we discussed the potential role of Epstein-Barr Virus or EBV in...
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.